One-carbon Therapeutics has partnered with Tempus AI to advance the clinical development of TH9619, a small molecule inhibitor of overexpressed enzymes in cancer cells.
One-carbon Therapeutics, headquartered in Sweden, is a clinical-stage precision oncology company focused on developing novel cancer therapies based on cancer biology. Tempus, a technology company, is focused on advancing precision medicine by applying AI to healthcare.
The collaboration aims to uncover deep molecular insights to aid the development of TH9619 through combining RNA sequencing data with clinical variables to analyse the expression landscape across prioritised solid tumour indications.
By doing this, the companies will build on its understanding of how cancer cells depend on one-carbon metabolism to potentially help identify patient population that are most likely to benefit from treatment.
Ana Slipicevic, CEO at One-carbon Therapeutics, said: “Understanding the molecular dynamics of one-carbon metabolism across tumour types and treatment settings is fundamental to advancing TH9619 with precision.
“Tempus’ depth of molecular data and analytical rigour enables us to generate statistically robust evidence that can potentially guide clinical decision making and optimise development.”
Through this new approach to understanding cancer cells, the companies aim to enhance development efficiency, reduce uncertainty and ensure that targeted therapies reach the patients most in need.
Ezra Cohen, Chief Medical Officer, Oncology, at Tempus, said: “Our goal is to accelerate progress in oncology by translating complex molecular insights into meaningful therapeutic advances.”
“Through comprehensive analysis of our multimodal data set, we are supporting One-carbon Therapeutics in characterising the metabolic signatures across diverse tumour types. These insights are essential to informing research strategies and advancing the development of next-generation targeted cancer therapies.”
TH9619 is currently being evaluated as a monotherapy for the treatment of patients with advanced refractory tumours in ODIN, a phase 1/2 first-in-human, multicentre, open label, dose escalation and expansion clinical study.
The trial is being conducted in the UK, France and Spain across academic and clinical research centres, with additional European sites to be added in the coming months.